This is the authors' abstract. We don't add key points for this paper.
Last December, two newspaper articles, one in the San Francisco Chronicle[1] and the other in the New York Times[2], reported on clusters of false-positive results of oral fluid rapid HIV testing in a number of settings. This led to fears among public health officials involved in HIV prevention efforts that the rapid tests for HIV, particularly those tests involving oral fluid specimens, were not performing as well in the real world as expected from studies in more controlled settings. Given the increasing popularity of rapid testing in the USA and elsewhere, the papers by Wesolowski et al. [3] and Delaney et al. [4] in this issue of AIDS are reassuring. In an evaluation of a combined total of over 38 000 oral fluid tests performed in a wide variety of clinical and non-clinical sites, rapid testing using oral fluid specimens, in general, performed well within the boundaries specified by the manufacturer of the test. While slightly more false positives were found with oral fluid compared to whole blood testing, the specificity in both studies fell within the 99.6–99.9% confidence interval listed by the manufacturer. There were a number of exceptions of sites where the test appeared to perform notably worse. However, in-depth investigation of these sites suggested that the false-positive test results may have been associated with remediable operant errors rather than poor performance of the test itself, although intrinsic problems with the use of oral fluid specimens due to cross-reacting antibodies may have also played a role. Why are these findings relevant? Enhancing HIV testing is increasingly seen as critical both in providing care to HIV-infected patients at an earlier stage and as an important tool in preventing the further spread of HIV. In the USA, a refocusing of HIV prevention efforts was heralded about 3 years ago by the Centers for Disease Control and Prevention (CDC) in their Advancing HIV Prevention initiative [5]. Among its four key recommendations, two relate to enhancing HIV testing: making testing routine in medical settings and to develop innovative ways to increase testing in high-risk, non-medical settings. In both settings, the rapid HIV test plays an important role in increasing test uptake. It is simple to use, specimens are easy to obtain, processing of the test can be done outside the laboratory in the field, and a quick turn-around time allows communication of results within 20 min, thus virtually guaranteeing that persons with positive tests obtain results immediately. The encouraging findings from Wesolowski et al. [3] and Delaney et al. [4] will no doubt lead to a further mainstreaming of HIV testing. Rapid testing allows for HIV testing on a routine basis in settings where high-risk individuals are frequently encountered, such as gay bars, bathhouses, and needle-exchange venues, as well as clinical sites where the challenge of scheduling follow-up visits has limited the broader implementation of standard HIV enzyme immunoassay (EIA). In these latter settings, including sexually transmitted infection (STI) clinics and emergency departments, HIV testing is increasingly offered as part of a standard package of services, unless the client/patient specifically declines to be tested for HIV; so-called ‘opt-out’ testing [6]. From an HIV medical care perspective, early detection of HIV is critical in effectively managing its sequelae. As was noticed recently in these pages, survival is significantly shorter in patients who initiate treatment when they have progressed to lower CD4 cell counts despite virological suppression [7]. While in the early years of the HIV/AIDS epidemic HIV testing was often actively discouraged because no treatment options were available, therapeutic interventions can now be life saving or at least can increase the quantity and quality of life, so that one can indeed argue that withholding or discouraging HIV testing is unethical. There is also growing consensus that the early diagnosis of HIV infection has prevention benefits. Those who are aware of their infections are significantly reducing high-risk behaviours, thus limiting the number of secondary infections compared to individuals who are unaware of their HIV serostatus [8]. Moreover, the cost-effectiveness of HIV counselling and testing as a means to prevent HIV transmission has been documented extensively [9]. While HIV testing is cost-effective and likely even cost-saving from a societal perspective, it should be noted that many HIV prevention programmes are cost-effective or cost-saving simply because HIV disease is so costly (US$200 000 for lifetime medical care costs alone). Thus even the prevention of one or a few cases may render a typical prevention programme cost-effective. As is true of many public health interventions, these savings do not often benefit the agency that incurred the costs of the prevention activities, but rather society at large, which has been reluctant to funnel those savings back to the prevention programmes. In fact, a paltry 4% of all federal HIV-related expenditures in the USA are used for prevention, and this proportion has been steadily declining over the years [10]. With the limited resources available, HIV prevention programmes thus have to be increasingly frugal in spending their funds. While not the intent of CDC's prevention initiative, a shift to HIV testing may thus come at the expense of other HIV prevention programmes. This may be problematic. A recently published modelling study supported by the RAND Corporation suggests that HIV counselling and testing in general may be less cost-effective than other prevention programmes, including community-level interventions targeting high-risk populations, needle-exchange programmes, and counselling and testing of partners of persons with HIV [11]. As with other modelling studies, the underlying assumptions in this study are debatable. Also, a strategy involving rapid testing without counselling was not considered. Nonetheless, there is no doubt that mainstreaming of new HIV testing modalities could lead to a watershed moment in the prevention and diagnosis of HIV akin to the advent of highly active antiretroviral therapy (HAART) in the treatment of HIV. It would be regrettable, however, if the emphasis on testing would eclipse prevention programmes that have proven their worth in the numerous studies spawned by the HIV epidemic over the past 25 years.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rietmeijer et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: